The last decade of research into the pharmacogenetics of antipsychotics has seen the development of genetic tests to determine the patients' metabolic status and the first attempts at personalization of antipsychotic treatment. The most significant results are the association between drug metabolic polymorphisms, mainly in cytochrome P450 genes, with variations in drug metabolic rates and side effects. Patients with genetically determined CYP2D6 poor metabolizer (PMs) status may require lower doses of antipsychotic. Alternatively, CYP2D6 ultrarapid matabolizers (UMs) will need increased drug dosage to obtain therapeutic response. Additionally, polymorphisms in dopamine and serotonin receptor genes are repeatedly found associated with response phenotypes, probably reflecting the strong affinities that most antipsychotics display for these receptors. In particular, there is important evidence suggesting association between dopamine 2 receptor (D2) polymorphisms (Taq I and À141-C Ins/Del) and a dopamine 3 receptor (D3) polymorphism (Ser9Gly) with antipsychotic response and drug-induced tardive dyskinesia. Additionally, there is accumulating evidence indicating the influence of a 5-HT2C polymorphism (À759ÀT/C) in antipsychotic-induced weight gain. Application of this knowledge to clinical practice is slowly gathering pace, with pretreatment determination of individual's drug metabolic rates, via CYP genotyping, leading the field. Genetic determination of patients' metabolic status is expected to bring clinical benefits by helping to adjust therapeutic doses and reduce adverse reactions. Genetic tests for the pretreatment prediction of antipsychotic response, although still in its infancy, have obvious implications for the selection and improvement of antipsychotic treatment. These developments can be considered as successes, but the objectives of bringing pharmacogenetic and pharmacogenomic research in psychiatric clinical practice are far from being realized. Further development of genetic tests is required before the concept of tailored treatment can be applied to psychopharmatherapy. This review aims to summarize the key findings from the last decade of research in the field. Current knowledge on genetic prediction of drug metabolic status, general response and drug-induced side effects will be reviewed and future pharmacogenomic and epigenetic research will be discussed.
Introduction
Pharmacotherapy is the mainstay of treatment for the psychotic symptoms of mental conditions such as schizophrenia, bipolar disorder and major depression and can be used for the treatment of psychotic symptoms of dementias. Antipsychotic drugs used for pharmacotherapy are traditionally classified into two major groups: classical (or typical) antipsychotics, with strong affinities for dopamine receptors among others, and the newer atypical antipsychotics, with multitarget profiles. 1, 2 Classical antipsychotics are effective for treating the positive symptoms of schizophrenia (hallucinations, delusions, thought disorder and disorganized behaviour) but are associated with extrapyramidal symptoms (EPS), some reversible (Parkinsonism, acute dystonic reactions and akathisia) and some long-lasting (tardive dyskinesia (TD) and dystonia). Atypical antipsychotics are used for the treatment of positive and negative (poverty of thought, blunted affect and social withdrawal) symptoms of the disease, and are characterized by a lower induction of EPS. However, this classification criterion has become somewhat imprecise in view of several new antipsychotics with pharmacological profiles comparable to that of classical antipsychotics (preferential affinity for dopamine receptors) and clinical profiles similar to that of atypical antipsychotics (improvement of positive and negative symptoms and low EPS risk). 1, 3, 4 In summary, uncertainty surrounds the mechanism of action of antipsychotic drugs, with no clear insight into the pathways of action.
Currently available antipsychotic drugs achieve a certain degree of clinical improvement in the treatment of psychosis in about 50% of schizophrenia patients. 1, 2, 5 Antipsychotic treatment failure has a substantial clinical and economic cost. Delay in finding an adequate treatment for psychosis has a detrimental effect on patients' prognosis and chances of recovery. [6] [7] [8] The economic costs are no less important, mental health services constitute 13% of British health expenditure with around d2500 millions (approximately $1800 millions) spent in the United Kingdom for the treatment of schizophrenia refractory patients. 9 Similar figures have been obtained in other countries. 10, 11 These strong implications reinforce the need for pharmacogenetic research into factors affecting antipsychotic response and ways to predict clinical outcome.
Are genetic factors involved?
Molecular genetic studies into disease-related factors are usually preceded by epidemiological investigations involving twin, family and adoption studies to determine the existence and extent of a genetic influence. Twin, family and adoption studies of psychotic disorders such as schizophrenia and bipolar disorder have provided strong evidence of a genetic contribution to their aetiology. [12] [13] [14] However, no similar studies exist in relation to response to antipsychotic treatment. Collections of monozygotic twins or family members concordant for disease and treatment are difficult to obtain and gathering the necessary epidemiological data has proved problematic to date. In the absence of a systematic epidemiological study, supporting evidence is limited to a number of case reports of monozygotic twins responding similarly to different antipsychotics: identical twins showing equal levels of response to treatment with the antipsychotics clozapine and olanzapine, and/or presenting the same adverse reactions (for example, weight gain and agranulocytosis) (Table 1) . 17, 18, 20, 21 Only one study presented a group of five monozygotic twins in comparison with seven pairs of same-sex siblings. 22 In this study, weight gain associated with clozapine treatment showed greater similarity in monozygotic twins than in same-sex siblings suggesting a genetic component for this side effect. Two studies observed concordance for drug-induced TD status in first-degree relatives, 15, 19 although a previous study in siblings had failed to find increased concordance in their response to neuroleptics. 16 Although scarce, such studies support the hypothesis of a genetic influence on antipsychotic response variability. However, the lack of a large twin study complicates the quantification of the genetic influence. Not knowing how strong the genetic factor is may hinder the determination of the number of genes involved and their identification. Genetic studies are made more complex by the widely recognized influence of additional factors such as environmental and clinical factors on antipsychotic response variability. Although it is not in the scope of this paper to review these nongenetic factors, a brief description will be given in a later section.
Pharmacogenetics of antipsychotics: research aims
The term pharmacogenetics was coined by Vogel in the 1950s to define inherited variability in response to drug treatment. 23 Initially aimed at finding enzyme mutations that resulted in individual's differences in drug metabolism, the field expanded to investigate genes controlling pharmacodynamic processes. Pharmacogenetic research into dynamic interactions began as a means of validating therapeutic targets and clarifying antipsychotics' mechanism of action. Most available antipsychotics have a multitarget profile 24 without any clear mechanism of action. Identification of target mutations with a direct influence on treatment outcome would constitute near-conclusive evidence of specific mediators of drug activity. This approach was used in genetic association studies and dopamine and serotonin receptors were clearly identified as targets of therapeutic value (Table 3) . Research aims were more ambitious in the late 1990s and attempts to combine pharmacogenetic information for the prediction of response to antipsychotic treatment met with varied success. Technological Table 1 Twin and family studies comparing response to antipsychotic treatment (MZ = monozygotic twins)
Reference
Reported observation
Waddington and Youssef 15 Concordance in neuroleptic-induced movement disorders 12 siblings from large pedigree DeLisi and Dauphinais 16 No increased concordance in siblings in their response to treatment with neuroleptics Vojvoda et al. 17 MZ pair concordant for response to clozapine Horacek et al. 18 MZ pair presenting agranulocytosis after clozapine treatment Mü ller et al. 19 Tendency of first-degree relatives (N = 19) to show concordance in tardive dyskinesia status Mata et al. 20 MZ pair concordant for olanzapine response Wehmeier et al. 21 Similar clozapine-induced weight gain in a pair of MZ Theisen et al. 22 Greater similarity of clozapine-induced weight gain in MZ in comparison with same-sex siblings advances in genetic analyses have greatly facilitated and accelerated investigations. However, there is still much research to be done before tailored treatment of schizophrenia can be considered.
Strategies and confounding factors
Pharmacogenetic research has been marred by a number of findings that have proved difficult to replicate in independent investigations. Aside from type I and II errors, the reasons for discrepancies in findings are manifold, ranging from heterogeneity of contributing factors to clinical and environmental differences between study samples. Arguably, many associations classified as type I errors should be reconsidered in view of the existing clinical differences between samples. Given that the basic conditions for genetic studies are considered (for example, ethnicity, sample size, magnitude of genetic effect and reliability of clinical data), other factors may affect the outcome of a pharmacogenetic study. Different drug types, treatment duration, response assessment methods may significantly alter study results, and without negating findings, clinical differences make the replication of results extremely problematic. 25 Although attempts have been made at standardizing the requirements for pharmacogenetic studies, 26, 27 the difficulty of collecting appropriate cohorts for the study of response traits means that some level of spurious findings will remain. In general, large samples (N > 1000) are recommended for pharmacogenetic studies investigating the relevance of genetic variants in drug kinetics. 26 However, reasonably reliable studies can be achieved with smaller sizes (N = 200-1000) with a balanced sample (for example, 1:1 ratio of treatment responders versus nonresponders) if a genetic effect of moderate magnitude is expected (odds ratio (OR) > 2) and the polymorphism investigated in relatively frequent (rare allele > 5%). However, none of these strategies will compensate for the necessity to confirm significant findings in independent samples that are as clinically similar as possible and for the possibility that clinical confounding factors may have different weights in different samples. Undoubtedly the introduction of pharmacogenetic tests in the clinical arena will be facilitated if they are robust enough to stand out above the 'noise' of different clinical settings.
Genetic and nongenetic factors of treatment variability
In the absence of detailed epidemiological information, the magnitude of the influence of genetic factors on treatment variability is unclear. A safe hypothesis will describe variability in response to antipsychotic as a complex trait influenced by clinical, environmental and genetic factors. The following sections will review significant evidence on the influence of these factors. Several literature searches using search engines PubMed, Embo, Medline and ISI web of Science were performed to find relevant information. Searches using the terms 'antipsychotic' and 'gene' or 'polymorphism' produced 770 references. More specific searches including the name of a neurotransmitter system (for example, 'dopamine') or metabolic enzyme (for example, 'CYP') and the words 'antipsychotic' and 'gene or polymorphism' were also performed to minimize the chances of missing relevant information. Material presented at meetings and conferences was not included on the basis that study results may vary when completed. When available, ORs and other measurements of the genetic effect reported in positive findings have been added.
Clinical and environmental factors
Smoking habits, diet and clinical and demographic factors have been described as factors influencing variability in drug response. The strength of each factor contribution may vary according to geographical and time differences. Environmental factors such as cigarette smoking and diet can induce or saturate metabolic pathways, directly affecting plasma levels of antipsychotic metabolites. These factors may be subject to geographical variation according to smoking and eating habits. Previous knowledge of patients eating and smoking habits can be used as an indicator for the adjustment of therapeutic doses. 28, 29 Response to the atypical antipsychotic clozapine has been reported to be influenced by clinical and demographic factors. Male gender and early age of onset predict poor response, whereas presence of EPS with previous treatments and paranoid symptoms predict good response to treatment with clozapine. 30 Male gender, fewer previous hospitalizations and higher therapeutic doses predict better treatment response to risperidone in combination with other genetic factors. 31 Two independent studies associated duration of treatment (DUP) with antipsychotic response whereby longer DUP predicted lower response to antipsychotics in first-episode schizophrenia, 32 and shorter duration of untreated psychosis (DUP) and good premorbid function were both independently associated with better response to olanzapine or haloperidol. 8 A combinatorial analysis of duration of illness, baseline score, family history and paranoid-type predicted response to neuroleptics. 32 However, in all cases only small to moderate effects were observed which have no bearing in clinical applications. Nevertheless, their importance should not be ignored and clinical and environmental factors, together with genetic determinants of response, should be considered when selecting treatments (see published articles in this area in a latter section).
Pharmacokinetic factors
The contribution of kinetic factors to the clinical outcome of antipsychotic treatment has a strong evidence base. Genetic variants in Phase I and II enzymes are known to reduce or increase their activity and subsequently to alter drug metabolic ratios. Excellent papers have been published on the subject 28, 29, [33] [34] [35] and only a summary of key findings relevant to schizophrenia will be covered in this review.
Phase I oxidation reactions are mainly involved in the metabolism of antipsychotic drugs. Table 2 presents a brief compilation of reported metabolic pathways and other relevant issues for commonly used antipsychotic drugs. CYP2C19 may be clinically relevant for the metabolism of antidepressants but has very limited significance for antipsychotic metabolism. Genetic variability in these enzymes has consistently been associated with drug metabolic ratios. 29, 35, 58, 59 Poor metabolizers (PMs), extensive metabolizers (EMs) and ultrarapid metabolizers (UMs) are phenotypic presentations of individuals carrying defective, normal or duplicate copies of CYP genes, respectively. A number of relatively common b More detailed information about drug-drug interactions is provided in. 37 Another review provided rough estimations of the effects of the drug-drug interactions on the plasma levels. 36 Anticonvulsant inducers (for example, carbamazepine, phenytoin and phenobarbital) have power effects in reducing antipsychotic levels by inducing CYP3A and/or UGTs. Smoking induces CYP1A2 and UGTs. See de Leon et al. 36 and Spina and de Leon 37 for a complete list of CYP inhibitors. Nefazadone is a powerful CYP3A inhibitor. Paroxetine and bupropion are CYP2D6 inhibitors. Fluvoxamine is a powerful CYP1A2 inhibitor and probably inhibits others including CYP2D6, CYP3A and CYP2C19. Fluoxetine (and its metabolite) are powerful CYP2D6 inhibitors and probably inhibits others including CYP3A and CYP2C19. Sertraline in high doses may inhibit CYPs including CYP2D6. c PgP is an ATP-dependent efflux pump located in several organs and is a major component of the blood-brain barrier. PgP has similar substrates, inducers and inhibitors as CYP3A. The role of PgP in blood-brain behaviour has been only recently demonstrated by in vitro studies of antipsychotics 56, 57 thus the results of this table need to be considered as provisional. d Some articles suggested that haloperidol may be metabolized by CYP1A2 since smoking induces haloperidol metabolism. More recent articles 38 suggest that smoking may induce haloperidol metabolism by inducing UGTs.
polymorphisms associated with these phenotypes have been described. A dedicated web page for the compilation and description of variants detected in CYP enzymes has been created (http://www. cypalleles.ki.se/).
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CYP2D6 is the main metabolic pathway of many antidepressants and a number of classical antipsychotics. 35 The gene coding for this enzyme is highly variable, with more than 90 mutations described. 28 Of these, four polymorphisms (*3, *4, *5 and *6) are responsible for most inactive alleles (98%) in Caucasians. 60 Some gene duplications (or more rarely multiplications) are responsible for UM phenotype. Not all CYP2D6 duplications are associated with increased activity, only the presence of CYP2D6*1XN, *2XN and *35XN duplications with an active allele in the other chromosome are associated with a CYP2D6 UM profile. 61 The frequencies of these polymorphisms are subject to geographical variation, with PMs representing 7-10% of Caucasians and 1-2% of Asians. Accumulating evidence indicates that the metabolic ratio of antipsychotics substrate for CYP2D6 can be affected by these genetic variants. Kirchheiner et al. 28 have demonstrated that the metabolism of the classical antipsychotic haloperidol is severely reduced in PMs, and a reduced therapeutic dose should be used accordingly. Alternatively, UMs require higher therapeutic doses to compensate for the rapid elimination of drug metabolites. In recent studies, it was observed that CYP2D6 did not predict response to risperidone, but predicted metabolic ratios and side effects. [62] [63] [64] No association was found between CYP2D6 PM variants and clozapine response. 65 However, small adjustments of therapeutic doses of clozapine are recommended according to CYP2D6 genotypes, suggesting that these enzymes are only minor pathways for clozapine metabolism. 28 Failure to respond to treatment with atypical antipsychotics was not determined by CYP2D6 UM alleles, although a trend towards an increase of UM variants in the treatment nonrefractory group was observed. 66 This apparent contradiction may be explained by a compensating higher dose in UM patients. Unfortunately, no dosage information was available in the study and this possibility could not be tested. The contribution of CYP2D6 polymorphism to the development of TD and other side effects is discussed later.
The cytochrome P450 1A2 (CYP1A2) is the main metabolic pathway of the antipsychotics clozapine and olanzapine. 43, 51 Several polymorphisms have been reported in the CYP1A2, with three variants showing decreased activity (*1C, *1K and *11). 67, 68 In addition, smoking seriously affects the activity of CYP1A2, with smokers displaying a higher metabolic rate, 69 in particular those with *1C and *1D variants. 70 However, CYP1A2 polymorphisms did not significantly influence individuals' clozapine metabolic capacity, 71 although delays in response to clozapine have been observed in individuals with the UM phenotype.
72,73 Also a combination of high inducibility CYP1A2 alleles and smoking may result in higher metabolic ratios and reduced clozapine plasma levels. 74 In these cases, an adjustment of therapeutic dose is recommended.
Numerous variants of the CYP3A4 enzyme, involved in the metabolism of most antipsychotics, have been described. However, only CYP3A4*17 and *18A, display functional variability with a decreased or increased activity, respectively. 75 To date, no significant reports of the associations of these variants with antipsychotic variability have been published. No significant response associations have been reported with the polymorphic CYP3A5, an enzyme reported to contribute to antipsychotic metabolism. 44, 63, 76 Several variants related to decreased activity of CYP2C9 and CYP2C19 have been detected, 77, 78 and one CYP2C19 variant (*17) with increased transcription in vitro has been described. 77 Aside from lower dose requirements, 28, 79 no connection between these variants and level of response to psychotropic drugs has been reported. CYP2C19 may be clinically relevant for the metabolism of antidepressants but has very limited significance for antipsychotic metabolism.
Phase II enzymes, relatively understudied in comparison with Phase I enzymes, are responsible for the inactivation of drug metabolites via conjugation reactions. N-acetyltransferases (NATs), thiopurine S-methyltransferases, UDP glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs) are major enzymes involved in Phase II reactions. However, no reports exist of the influence of Phase II enzyme variants on antipsychotic efficacy. Nevertheless, recent investigations have suggested that Phase II enzyme variants may contribute to treatment variability and disease aetiology, in particular to those related to environmental toxic compounds (for example, cancer). 80 Functional polymorphisms have been described in the UGT gene that may influence the metabolism of clozapine and other antipsychotics, but no statistically significant associations have been reported. 81 These studies have proved that genetically determined metabolic alterations have important implications for therapeutic dosage and may be related to toxic accumulations inducing side effects (see relevant section), although no clear picture of their influence on final response has been established. Nevertheless, pharmacogenetic studies of kinetic factors have provided the most significant and clinically applicable results in psychiatry to date. Genetic determination of patients' metabolic status may have a clear beneficial effect on antipsychotic treatment. It has b een estimated that pretreatment metabolic determination may decrease adverse reactions by 10-20% and improve efficacy by 10-15% (probably by increasing treatment adherence). 82 Aside from genetic determinants, metabolic rates can also be influenced by concomitant treatment and the inhibitory or inductive action of certain drugs ( Table 2 ). Concomitant treatment with drug substrates for the same enzyme may lead to saturation and toxic metabolite accumulation. Additionally, antidepressants and classical antipsychotics are known to inhibit hepatic enzymes which may result in elevated levels of drug metabolites with toxic consequences (newer atypical antipsychotics have a negligible effect). 34, 40 CYP-inductor drugs may affect plasma concentrations of antipsychotic compounds with potential clinical implications. In a pharmacogenetic study, CYP inhibitors and inducer significantly predicted risperidone discontinuation due to side effects but did not significantly predict risperidone side effects. 63 Other environmental interactions, for example, smoking and caffeine, may also influence CYP activity and by extension antipsychotic metabolism. The influence of smoking on CYP1A2 and UGT induction is well documented and recommendations for dose adjustments according to the patients smoking habits already exists. 36, 83 Caffeine intake inhibits CYP1A2 rates and may also have clinical implications. 36, 84 Treatment with olanzapine and clozapine, both antipsychotics mainly metabolized by CYP1A2 and UGT enzymes, may be affected by smoking and caffeine intake and therapeutic doses should be varied accordingly. It is important to consider these environmental factors when contemplating treatment with drugs with a narrow therapeutic window or with only one or two major pathways.
Pharmacodynamic factors
Pharmacogenetic research into dynamic factors started as a strategy for the validation of therapeutic targets. Traditionally, neurotransmitter systems observed to be altered in brains of schizophrenia patients have been used as targets for antipsychotic therapy. Most modern antipsychotics display a wide range of affinities for neurotransmitter receptors, including dopamine, serotonin, histamine, muscarine, glutamate and adrenergic receptors, 24 all hypothetically relevant to the aetiology of schizophrenia. Varied pharmacological profiles denote complex pathways, and subsequently little is known of the molecular mechanisms of antipsychotic activity. Identification of genetic variants of neurotransmitter receptors associated with levels of response can confirm their mediation of antipsychotic activity. On the basis of this assumption, genetic association studies on receptor polymorphisms have attempted to identify receptors of therapeutic value. Response-related receptor variants may also contribute to disease aetiology, particularly in cases where treatment is directed to brain areas affected by the disease. Alternatively, response-related variants may be found in drug-targeted areas indirectly related to disease via interactions with disease-affected systems. The next sections will review these results, commenting on the most significant findings of pharmacogenetic studies on drug-targeted receptors.
Dopamine. Accumulating evidence suggests the importance of the dopamine system in mediating antipsychotic activity. Dopamine alterations in the brain of schizophrenic patients were among the first pathological observations in schizophrenia research, and, for this reason, the classical type of antipsychotics had preferential affinity for dopamine receptors. Targeting of dopamine receptors has been associated with amelioration of positive psychotic symptoms, and is a characteristic of both first-and second-generation antipsychotics. Existing evidence indicates that dopamine antagonism is required for antipsychotic activity. Positron emission tomography (PET) studies have shown that a minimum occupancy of 60% of striatal D2-like receptors is required to obtain clinical response. However, dopamine blockade in the striatum (D2 occupancy above 80%) is also considered to be the main cause of extrapyramidal side effects related to acute movement disorders. 1, 3, 85 A relatively recent hypothesis suggests that moderate dopamine receptor occupancy and fast dissociation could confer antipsychotic activity without causing extrapyramidal side effects. 86, 87 Of the five types of dopamine receptors (D 1 -D 5 ), D 2 and D 3 are the most strongly targeted by antipsychotic drugs.
Several studies have associated D 2 genetic variants with response to classical antipsychotics, [88] [89] [90] [91] [92] but also with response to clozapine, olanzapine (atypical antipsychotics) and risperidone (an atypical antipsychotic with strong D 2 binding). [93] [94] [95] [96] In particular, the Del allele of a À141-C Ins/Del polymorphism was associated with lower improvement after antipsychotic treatment in two independent studies 88, 89 (see Table 3 ). Conflicting reports associate the À141-C Del allele with lower expression of the D2 receptor in vitro, 159 and higher D2 density in the striatum in vivo, 160 making it difficult to discern a plausible biological explanation for this finding. The hypothesis for the involvement of the dopamine system in the aetiology of the positive symptoms of schizophrenia is further reinforced by findings of an association between a D3 Ser9Gly polymorphism and improvement in positive symptomatology after antipsychotic treatment. 100, 104 This same polymorphism has also been associated with general response to treatment with classical and atypical antipsychotics. 31, 101, 102 In vitro studies indicate that the Gly variants is associated with higher dopamine binding affinity. 161 However, the biological interpretation of this observation is difficult, as the Gly variants was mostly associated with good response in Caucasian patients 101, 102, 104 and with poor response in Chinese populations, suggesting that linkage disequilibrium (LD) status with another functional polymorphism may explain the different associations with response.
An elevation of D4 receptors in the brain of schizophrenic patients, and the observation that D4 receptors were more strongly targeted by clozapine than D2 receptors led to the hypothesis that D4 receptor mediated clozapine antipsychotic efficacy. 86, 162 A 48 bp repeat detected in the third intron of the gene coding for the D4 receptor was found to be Abbreviations: CI, confidence interval; NR, nonresponders; OR, odds ratio; R, responders to treatment; SNP, single-nucleotide polymorphism.
Pharmacogenetics and pharmacogenomics of schizophrenia MJ Arranz and J de Leon associated with response to the antipsychotics clozapine and risperidone, [105] [106] [107] although these studies were of moderate size and required further confirmation in larger samples. Three independent studies failed to confirm these associations. [108] [109] [110] Studies of genetic variants in the dopamine transporter gene (DAT1) reported several associations between a VNTR polymorphism and response to methylphenidate, a treatment for attention deficit and hyperactivity disorder (ADHD), 163, 164 but no association has been reported with antipsychotic response. 102, 103, 111 The final reading of these association findings is that they confirm the contribution of dopamine receptors to antipsychotic efficacy. In particular, the associations with response to antipsychotics with strong dopamine blockade properties (for example, risperidone and haloperidol) seem to reflect the mediation of these receptors in their activity.
Serotonin. The serotonin hypothesis of schizophrenia arose as a result of the hallucinogenic properties of LSD and other compounds that targeted serotonergic receptors. Interactions between serotonin and the dopaminergic and glutamatergic systems, also involved in schizophrenia aetiology, further strengthen the candidacy of these receptors.
Alterations of the serotonergic system have been implicated in depression, anxiety, eating disorders and negative symptoms of schizophrenia. [165] [166] [167] [168] Traditionally, strong targeting of serotonin receptors relative to dopamine receptors (as measured by the 5-HT 2 /D 2 binding ratio) was described as the main characteristic of atypical antipsychotics such as clozapine, risperidone and olanzapine. 85, 169 However, it is not clear that this is the reason for their therapeutic efficacy because success has also been achieved using novel antipsychotics with low serotonin affinities. 1, 3, 4 Of the serotonin (5-HT) receptors, the 5-HT 2A and 5-HT 2C subtypes have been the most extensively studied. Neuroimaging studies revealed high occupancy of 5-HT 2 receptors by atypical antipsychotics, and indicated that this high occupancy was associated with improvements in negative symptoms and cognition. 170 A number of reports have associated a silent 5-HT 2A polymorphism, and a 102-T/C substitution, with response to clozapine and risperidone. 116, 121, [123] [124] [125] This polymorphism is in complete LD with a À1438-G/A promoter polymorphism in Caucasian populations (the extent of linkage may vary in different ethnic groups). The G allele of this last polymorphism shows a lower promoter activity than the A allele 171 and may partly explain the associations with response. 121, 126, 127 A second study did not find differences in expression between both alleles, but found that the À1438-G allele was associated with decreased promoter activity when expressed in combination with a À783-G variant in the same gene. 172 The G allele tends to be associated with poorer response, suggesting that a lower expression of the receptor protein may decrease the efficacy of the dopamine-serotonin regulation exerted by antipsychotics. An amino-acid substitution in the same gene, His452Tyr, was also found to be associated with clozapine response. 128, 129 Although several other reports failed to find these polymorphisms significantly associated, [117] [118] [119] [120] 122 a meta-analyses showed a clear association of the Tyr variant with poor response to clozapine (OR = 5.55). 121 The Tyr variant of this polymorphism is reportedly associated with reduced calcium release and reduced ability to activate phospholipases C and D, 173, 174 which may lead to a reduced signal and indirectly to a lower efficacy of the targeting antipsychotics. Genetic variants in the promoter (VNTR, À759-T/C and À995-G/A), and coding region (Cys23Ser) of the 5-HT 2C receptor have also been associated with clozapine response and improvement in negative symptoms, 100, 130, 132 as well as with drug-induced side effects (reviewed later). These findings reinforce the assumption that 5-HT 2 receptors mediate antipsychotic activity. However, the contribution of 5-HT2 variants to general response is relatively moderate, possibly indicating contribution to specific symptoms or side effects that require explicit investigation. There are other reported associations of 5-HT 6 receptor variants with clozapine and risperidone response in Chinese patients, 135, 137 who still require further replication in independent studies. 136 The 5-HT1A receptor is hypothetically involved in negative, cognitive and depressive symptomatology and is implicated in antidepressant drug action. Although not a particularly strong target for modern antipsychotics, it may influence efficacy by regulating other serotonin and dopamine receptors. A recent study provides support for this theory by reporting association between a 5-HT1A -1019-C/ G polymorphism and antipsychotics improvement of negative symptoms. 115 Further evidence exists of the likely involvement of other serotonin receptors in antipsychotic activity (for example, 5-HT 3A , 5-HT 3B , 5-HT 5A and 5-HT 7 ). However, few genetic studies have attempted to confirm this hypothesis 133, 134 and no significant association with antipsychotic response has been reported to date.
Aside from receptor variants, alterations in serotonin synaptic levels may also influence antipsychotic response. Polymorphisms in the serotonin transporter (5-HTT) have been investigated in relation to antipsychotic response. In particular, a functional polymorphic VNTR in the promoter region of the 5-HTT coding gene was found to contribute to clozapine response, 132 although later reports in Caucasian and Chinese patients did not confirm this finding. [138] [139] [140] The strong influence of 5-HTT variants observed in treatment with antidepressants (see reviews by Serretti et al. 175, 176 ) is not reflected in studies on antipsychotic response.
Glutamatergic system. Malfunction of the glutamatergic system, leading to excessive stimulation of dopamine receptors, has been hypothesized as one of the causes contributing to the aetiology of schizophrenia. [177] [178] [179] [180] [181] Recent reports of altered glutamatergic activity appear to corroborate the hypothesis. 178, 182, 183 Additionally, compounds acting on N-methyl-D-aspartate (NMDA) receptors reduce negative symptoms and cognitive impairments of schizophrenia. 180 It has been suggested that NMDA may mediate, at least partially, the activity of antipsychotic drugs, in particular of olanzapine and risperidone. 184, 185 The pharmacogenetics of the glutamatergic system remains comparatively understudied, and no clear associations have been established between antipsychotic treatment and glutamate variants. GRM3 genotypes were associated with negative symptom improvement after treatment in a small sample of Caucasian patients. 112 Chiu et al. 186 found an association between NMDAR1 receptor variants and clozapine dosage. Hong et al. found no correlation between NMDA receptor subunit 2B (GRIN2B) genetic variants and clozapine response. This lack of significant evidence is probably the result of insufficient studies of this complex system.
Other neurotransmitter systems. Most modern antipsychotic profiles include relatively strong affinities for adrenergic, histamine and muscarinic receptors. These receptors are hypothesized to play a role in determining cognition, a function severely impaired in schizophrenia patients. a1-and a2-adrenergic receptors are strongly targeted by conventional and modern antipsychotics. However, little genetic evidence of their contribution to treatment variability exists. [97] [98] [99] In our laboratory, we found marginal associations between a1-and a2-haplotype combinations and symptomatology after treatment with olanzapine and risperidone (Daniel Clark, Institute of Psychiatry, London, personal communication), although no individual polymorphism was found to be strongly associated with response. Histamine 1 (H 1 ) and histamine 2 (H 2 ) receptors are strongly targeted by atypical antipsychotics, and by drugs that treat negative symptoms. However, no clear evidence of their role on treatment response has been obtained. 114, 132 Targeting of muscarinic receptors has been suggested to contribute to the beneficial actions of clozapine, as suggested by in vitro studies. 187, 188 Marginal associations detected in our laboratory (Dalu Mancama, Institute of Psychiatry, London, UK, personal communication) agree with this assumption. However, no published study presents evidence supporting this hypothesis.
Even considering that for nearly all mentioned positive associations there are a number of nonreplicative reports (and possibly unpublished negative studies), pharmacogenetic studies seem to confirm that dopamine and serotonin systems contribute, at least partially, to the antipsychotic properties of current medications. Additionally, the reported associations confirm the utility of pharmacogenetic studies to identify receptors, among those targeted by multitarget drugs, with a role in their antipsychotic efficacy. However, further research is required to clarify the contribution of other targeted receptor systems. It is quite unlikely that, given the multitarget profile of most currently available antipsychotics, only dopamine and serotonin receptors contribute to their antipsychotic efficacy. Glutamatergic receptors are likely to have a greater contribution to treatment variability than detected, whereas relatively major contributions to general response and specific response traits (for example, cognitive impairment and weight gain) are hypothesized of adrenergic, histamine and muscarinic variants.
Developmental and regulatory genes
Recent hypotheses have suggested the involvement of genes regulating neuronal genesis, plasticity and interactions in the pathophysiology of schizophrenia. This hypothesis, supported by genetic evidence, 189 widens the possibilities for symptom variability and antipsychotic activity. Alterations of proteins not directly targeted by antipsychotic drugs may lead to different pathology and symptomatology, creating patient subgroups that may respond differently to pharmacotherapy. Subsequently, the scope of pharmacogenetic studies has expanded to genes coding for proteins involved in the regulation of neural metabolism, development and functionality.
Because of the importance of the dopamine system in antipsychotic activity, proteins regulating dopamine availability or functionality may influence response to treatment. The catechol-O-methyltransferase (COMT) enzyme that catalyses the degradation of dopamine and limits its availability falls within this group. In addition, significantly increased mRNA COMT levels have been observed in the frontal cortex of rats treated with risperidone and olanzapine, supplying a possible explanation for the cognitive improvements observed after treatment with these two drugs. 190 Marginal associations have been described between the functional COMT Val108/158Met polymorphism and response, with individuals presenting the low methylation Met variable showing better response. [144] [145] [146] [147] The biological significance of this finding (theoretically the Met variant would be associated with dopamine accumulation and postsynaptic receptor supersensitivity) is not clear. Variants of the dopamine receptor-interacting protein gene (NEF3) were also found marginally associated with treatment response. 153 Both results contribute to the mounting evidence of the therapeutic importance of the dopaminergic system. A study of genetic variants in the neurotensin receptor (NTSR1) that regulates dopamine transmission in nigrostriatal and mesocorticolimbic systems did not add to the existing evidence. 155 Functional alterations in second messengers may influence the level of signal response after receptorantipsychotic interactions. Most monoaminergic receptors targeted by antipsychotics are coupled to G proteins, and several studies have investigated genetic variants in G-protein-related genes. A 825ÀC/ T polymorphism in the G-protein b 3 -subunit gene (GNB3) was associated with variation in BPRS scores after treatment in a sample of US patients. 148 However, no association was found when investigating variants of the regulator of G-protein signalling 4 (RGS4) gene. 156 The multidrug-resistant P-glycoprotein (MDR1, also known as ABCB1) is a transmembrane protein that regulates the absorption, distribution and elimination of xenobiotics in the blood-brain barrier, playing an important role in the accumulation of drugs in the brain ( Table 2) . Overexpression of this protein may result in drug resistance. Positive findings of association between MDR1 polymorphisms (2677-T/T and 3455-T/T) with better response and cognitive improvement 150, 151 were not supported in a recent study. 149 However, the biological importance of alterations in MDR1 activity warrants further investigation of its genetic variants.
Strong evidence supports the involvement of genetic variants of the neuregulin 1 gene (NRG1) in the aetiology of schizophrenia, 191, 192 although its involvement in treatment variability is less clear. However, it has been suggested that NRG1 may play a role in clinical outcome via regulation of glutamate, GABA and acetylcholine receptors, a hypothesis supported by a positive finding of association between a NRG1 polymorphism and treatment response. 154 The brain-derived neurotrophic factor (BDNF) is involved in the development, survival and functional maintenance of neurons, and plays a role in the regulation of expression of dopamine-related systems. BDNF variants have been related to schizophrenia, but only marginal association or negative significance has been described in relation to treatment response. [141] [142] [143] NOTCH4, a developmental gene also involved in the regulation of neuron generation from stem cells, was not found individually associated with response but was suggested to interact with COMT to influence clinical outcome, 145 although the validity and biological significance of this finding requires investigation. The tumour necrosis factor-a (TNF-a) is a cytokine that mediates host response during inflammation and infection, and has been suggested to play a role in neurodevelopment and degeneration. 158 American patients possessing two copies of the A variant of a TNF-a promoter polymorphism (À308-G/A) showed higher improvement after 6 months of treatment, 158 a finding not replicated in a study including Chinese patients. 157 Finally, a silent 677-C/T polymorphism in the gene coding for methylenetetrahydrofolate reductase (MTHFR) enzyme has been associated with neuroleptic response, with individuals possessing a copy of the T allele showing better improvement with treatment. 152 This enzyme is required for the synthesis of 5-MHTF, a cosubstrate for the conversion of homocysteine into methionine. High levels of homocysteine have been observed in schizophrenia patients, and may be related to the ability to respond to treatment. 152 Most of the findings reported in this section are recent publications, and more research will be required to confirm their significance. However, they constitute an interesting expansion of the candidate gene pool from already known target genes to novel proteins with potential therapeutic value.
Tailoring antipsychotic treatment
The ultimate goal of pharmacogenetic research is the application of knowledge to clinical practice. Valuable applications in the prediction of metabolic status have already been identified, whereas important progress towards the prediction of general response and drug-induced side effects has been achieved. The current knowledge in these areas is reviewed in the following sections.
Prediction of drug metabolic status
Genetic knowledge of patients' drug metabolic status can be used for the adjustment of therapeutic doses accordingly. Kirchheiner et al. 26, 28, 33 have published several studies recommending adjustment of the therapeutic doses of antidepressants and antipsychotics according to CYP2D6, CYP2C9 and CYP2C19 phenotypes. By reducing the dose in PM patients or increasing it for UM patients treated with substrate drugs, therapeutic levels can be obtained without toxic metabolite accumulation. The authors claim that a 10% reduction in the development of side effects can be achieved using this strategy. Arguably, this strategy may have greater benefits for antidepressant treatment than for antipsychotic drugs. Genetically determined metabolic polymorphisms are more likely to influence treatment with antidepressants, mainly metabolized by the highly polymorphic CYP2D6, than treatment with antipsychotics, with a wider range of metabolic pathways in general. Nevertheless, this is an important pharmacogenetic improvement for psychiatric treatment. Several rapid methods for individual determinations of common metabolic polymorphisms suitable for clinical laboratories are available. [193] [194] [195] On a different scale, most clinical trials incorporate genetic determination of CYP enzymes using high-throughput genotyping techniques. 196, 197 Recently, commercial arrays have been made available for the rapid genotyping of common CYP2D6 and CYP2C19 polymorphisms. 61 These arrays contain information to identify the polymorphisms causing more than 90% of PMs at risk of overdosing (these values correspond to European Caucasian frequencies and may vary among different ethnicities). 35, 77, 198 The implementation of these techniques in clinical practice can bring clear improvement to psychiatric treatment by averting toxic events and improving treatment adherence and efficacy.
Prediction of general response
Most genetic findings are of limited clinical value if taken individually. Their contribution to response traits is relatively small as reflected by their moderate ORs ( < 2.0 in most cases). Combinatorial strategies combining genetic information in key target receptors and enzymes may improve their global predictive value. The first attempts at genetic prediction of treatment response were made on the drug clozapine, a potent antipsychotic used for the treatment of refractory patients, in spite of its induction of severe agranulocytosis in about 0.7% of treated patients. Being restricted to refractory patients and with a high cost, clozapine use has been lower than expected for such a successful antipsychotic drug. Therefore, methods to identify patients who could benefit from this successful drug at an early stage were sought. Individual association studies had identified several variants in clozapinetargeted receptor with influence on clinical outcome. 114, 121, 126, 129, 199 We combined information of genetic variants associated with response and developed an algorithm for the prediction of clozapine outcome. A combination of variants in the genes coding for 5-HT 2A , 5-HT 2C , H 2 receptors and for the serotonin transporter 5-HTT resulted in the correct prediction of response in 76% of cases. 132 Our preliminary findings were not replicated by an independent study made on German patients. 200 However, the reasons for this discrepancy were clear differences in the clinical characteristics (for example, different length of treatment and different response assessment) of the study samples 25 and had been highlighted in previous studies. 121 However, the validity of the approach should not be ignored. Although still needing replication in independent samples, the clozapine story has proved the feasibility of using genetic information for the prediction of general response. Pilot studies carried out in our laboratory have shown that similar tests can be devised for other antipsychotic drugs such as risperidone and olanzapine (unpublished data), combining genetic information in both metabolic enzymes and drug targets. 104 Arguably, these tests may not be as precise as tests based exclusively on genetically determined pharmacokinetic factors, given the complexities of pharmacodynamic processes and environmental interactions. Additionally, these tests may be suitable for specific clinical environments (for example, long-term clozapine treatment) as the discrepancies observed suggest. Adequate replication in different clinical environments and population groups is required to investigate the reliability and utility of these tests. Surprisingly, no publications of similar tests or replications of this study have been produced since, reflecting perhaps the current high costs of large sample recruitments.
These studies show that genetic prediction of response to antipsychotic treatment is ambitious but feasible. A more critical view that should also be considered is that very few, if any, pharmacogenetic tests may be able to stand the 'fire' of the clinical environment. Response to antipsychotic treatment in the real world is contaminated by a large set of complex clinical variables of the patients and even of the prescribers. This clinical environment has a substantial quantity of 'noise'. Only predictors that are strong and consistent enough to stand above the noise in different settings and countries may be generalizable to the clinical setting. Generalizability is a major problem for prognostic tests. 201 Genetic complexity due to uncertainty on the functionality of the single-nucleotide polymorphisms (SNPs) and haplotypes, and on racial variations are a particular challenge for developing genetic tests that can be marketed across different countries and races. A recent article also points out that an important area of human genome variation, the copy number variations (deletion and duplications) may have been ignored. 202 The development of technologies that permit massive and generalized genetic testing described at the end of this review should be heralded as a breakthrough, but at the same time as a major methodological challenge because we currently may lack the statistics techniques to determine which of the thousands of genetic variations that can be currently examined may be relevant and generalizable to different clinical settings. New methodological or even philosophical approaches in genetic statistics may be needed.
Nevertheless, any pretreatment genetic method that improves over the current trial-error strategy for the selection of antipsychotic treatment should be considered progress. The reliability and generalizability of pharmacogenetic tests can be improved by the addition of drug metabolic information, and consideration of clinical and environmental factors (see below).
Prediction of side effects
Prediction and prevention of side effects associated with antipsychotic treatment is as important, if not more, than prediction of treatment outcome. The severe and sometimes lasting side effects associated with antipsychotic treatment greatly contribute to treatment failure due to poor compliance. Determination of the related genetic factors is one of the main aims of pharmacogenetic research as a way of predicting and preventing them. Two particularly severe drug-induced side effects, TD and weight gain, have been extensively investigated, but comparatively less knowledge is available on the genetic contribution to agranulocytosis, neuroleptic malignant syndrome and other unwanted reactions associated with antipsychotic treatment. The current knowledge of the genetic contribution to these side effects will be discussed in the following sections.
Tardive dyskinesia. The mechanisms underlying the development of dyskinesias and other movement disorders are poorly understood. Supersensitivity of dopamine receptors, other neurotransmitters changes, and disturbances in antioxidative protection have been proposed as possible pathophysiological mechanisms. Additionally, development of EPS and TD has been directly associated with increases in drug dosage and plasma levels, which may exacerbate the pathophysiological mechanisms. Table 4 summarizes reported associations.
The D3 receptor is localized in brain areas involved in motor function, and it has been shown that antagonism of these receptors exacerbate brain locomotor activity. 288 Additionally, antipsychotics with relatively low D3 affinity, such as clozapine, are reported to cause significantly lower movement disorders in contrast to first-generation antipsychotics, characterized by strong dopamine antagonism. 87, 176, 289 Polymorphisms in D3 receptors were first reported to contribute to drug-induced TD by Steen et al. 230 and by Segman et al. 231 In both studies, individuals with one or two copies of the Gly allele of a D 3 Ser9Gly polymorphism were more likely to develop TD with antipsychotic treatment. Several subsequent studies failed to replicate this finding, 204 ,232-234 but a combined study of 780 patients of different ethnic background, 235 and further reports of association in the United States, Chinese and Korean patients 221, 236, 237 confirm the validity and strength of this finding. The Gly variant is reportedly associated with significantly higher dopamine activity, which in turn could explain the association with movement disorders. 238 Only one study reported the Ser/Ser genotype associated with increased risk of TD after correcting for age in a large Chinese cohort, 226 a contradiction that may be explained by different LD status in this population. A recent meta-analyses showed that the D3 Gly9 allele conferred an increased risk of developing TD (P = 0.04, O.R. = 1.17), with important geographical variation (OR = 1.07 in Asian populations, 1.39 in non-Asian populations). 238 In spite of the relatively moderate effect, the consistent replication of this finding in different population groups indicates a true involvement of D3 variants in the development of TD. However, the modest ORs also suggest further contribution of other genes in the development of this severe side effect. In a somewhat surprising result, Liou et al. 203 found no association between the D3 Ser9Gly polymorphism and TD in 216 Chinese schizophrenic patients (uncorrected for age), but reported association with heterozygosity for a BDNF Val66Met polymorphism. Srivastava et al. 204 also failed to find association between D3 polymorphism and TD, but reported association between COMT, the enzyme that controls dopamine turnover, and TD, a finding not confirmed by other independent studies. [205] [206] [207] 224 Similarly, MAOA and MAOB, two monoamine oxidases also involved in dopamine degradation, have been investigated and not found to contribute to TD, 207 suggesting that factors controlling dopamine metabolism are not involved. Two recent studies have reported association between D4 polymorphisms and drug-induced TD. A gene 120 bp duplication and the long allele of the D4 LPR were reported to decrease the risk of TD, 204, 224 increasing the evidence supporting the involvement of dopamine receptors in susceptibility to TD. The D3 Ser9Gly polymorphism was also associated with neuroleptic induced akathisia, 239 a common side effect which is thought to be triggered by alterations in nucleus accumbeus D3 activity. Other investigated dopamine receptors were not found to contribute to these adverse effects. Only one report suggested association between D2 polymorphisms and TD, 229 but no evidence was found by other groups. 204, [223] [224] [225] [226] [227] [228] Similarly, no association was found when investigating D1 polymorphisms and a polymorphism in the dopamine transporter (DAT) in relation to TD, 204 and no association was found between D2 and D3 polymorphisms and tardive distonia, an uncommon druginduced movement disorder, in a pilot study on nine patient sufferers. 240 Serotonin inhibition of dopamine function may also contribute to the pathological events related to movement disorders. Initial reports on association between 5-HT 2A polymorphisms and TD 224, 243, 244 were not replicated in independent studies. 205, 247, 246 The association was later confirmed in a combined analyses controlling for patients' age, 245 an important factor in the development of TD. Serotonin 5-HT 2C promoter polymorphisms were reportedly associated with TD. 248 This finding was not replicated in German and Indian patients. 246, 290 However, the German study did not correct for patient age and the second study included patients with a relatively low average age. Studies on 5-HT6 and 5-HTT polymorphisms failed to find any association. 205, 251, 252 Further studies investigating 5-HT 2C , 5-HT 2A and D 3 genotypes with age and disease phenotypes 249, 250 provided significant associations confirming the involvement of dopamine and serotonin systems in susceptibility to TD.
Oxidative stress caused by the increased formation of reactive oxygen species induced by antipsychotic treatment may result in neuronal degeneration and TD. Two antioxidant enzymes (glutathione peroxidase GPX1 and glutathione S-transferase GSTP1) involved in the detoxification of reactive oxygen species have been examined by Shinkai et al. 241, 242 with negative results. Nevertheless, evidence supporting this hypothesis was provided by studies investigating NAD(P)H quinone oxireductase (NQ01) and nitric oxide synthases (NOS1 and NOS3), three enzymes involved in the defence mechanism against oxidative stress. NQ01 polymorphisms were found associated with TD in Korean patients, 257 but not in Chinese patients. 258 Although no evidence could be found of a relation between NOS1 genetic variants and TD, 254, 255 positive associations with NOS3 polymorphisms 256 suggest a possible role of oxidative stress and neuronal damage in the development of TD. Finally, a study investigating the increased activity of plasma manganese superoxide dismutase (MnSOD) in TD failed to find a connection with the Ala9Val polymorphism and did not add to the existing evidence. 253 Genetically determined dysfunction of metabolic enzymes and the subsequent accumulation of drug metabolites significantly contribute to the development of adverse reactions. This hypothesis has been proved right in numerous reports of association between metabolic polymorphisms and side effects including TD and other movement disorders. Impaired activity of the CYP2D6 enzyme was associated with TD as early as 1995.
291 CYP2D6 PMs were found to be associated with risperidone adverse reactions and discontinued treatment in a study on US patients. 63 The same investigators reported association of TD with glutathione S-transferase GSTM1 polymorphisms, but failed to find associations with glutathione S-transferase GSTT1, D2 and MDR1 polymorphisms.
221 CYP2D6 PM variants have been found associated with TD, EPS, AIMS scores and parkinsonism in several studies including different ethnic groups. 211, 213, 215, 220 In a study in German patients, CYP2D6 genotype was as good a predictor of adverse events as plasma haloperidol concentrations, 217 and adds to the clinical value of CYP genotyping. CYP1A2 variants constitute genetic risk factors for the development of drug-induced TD as suggested by positive association findings. 208, 210, 211 Interestingly, Basile et al. 292 reported an additive effect between the D3 and CYP1A2 risk genotypes for TD. Individuals who were homozygote for the TD risk alleles D3 Gly and CYP1A2 C had the most severe TD, indicating an additive effect. Additionally, an interaction between the D3 Ser9Gly polymorphism and a polymorphism in the gene coding for the cytochrome P450 17a-hydroxylase was reported associated with abnormal involuntary movements in treated patients. 222 However, investigations on CYP3A4 and CYP3A5 genetic variants failed to find any relevant connections with side effects. 214, 221 In spite of several negative reports, 209, 212, 214, 216, 218, 219 the evidence supporting the involvement of CYP1A2 and CYP2D6 variants in drug-induced side effects appears convincing.
Weight gain. Side effects such as weight gain can be a serious impediment to successful pharmacotherapy. Similarities in drug-induced weight gain in monozygotic twins and siblings suggest a genetic component contributing to this side effect. 21, 22 Serotonin and histamine receptors have important roles in controlling eating behaviour and are obvious candidate genes for these studies. The adrenergic system is thought to play an important role in regulating energy balance via stimulation of thermogenesis and lipid mobilization in adipose tissue. Genetic variation in these receptors could alter lipolytic activity and contribute to weight alterations during antipsychotic treatment.
The most significant results associate 5-HT 2C receptor variants with drug-induced weight gain. Reynolds et al. were the first to report association between a 5-HT 2C À759-T/C polymorphism and weight gain. 268 This polymorphism has been reported to influence transcriptional activity with the À759-C allele showing comparatively less activity. 293 Although a number of studies failed to replicate this finding, 267, 269, 270, 294 later reports have confirmed the relevance of 5-HT 2C genetic variants to weight gain in different population groups. [272] [273] [274] 295, 296 In these studies, the 5-HT 2C À759-T was found to have a protective effect against weight gain with individuals having at least a copy of this allele showing less incidence of this side effect. Given the strength of the association (ORD6 268 ), this may be a finding with useful clinical application as predictor of weight gain during antipsychotic treatment. A À2548-G variant of the leptin gene, a hormone that also plays a role in the regulation of food intake, was found to be associated with weight gain after 9 months of weight gain, but not in the short term in first episode patients. 273 However, the functionality of this polymorphism has yet to be determined. The G variant of a À1291-C/G promoter polymorphism in the a-adrenergic receptor gene (ADRA2A) was significantly associated with clozapine and olanzapine weight in two separate studies in Chinese and Korean patients, respectively. 260, 261 As the functional effect of this polymorphism is unknown, it is only possible to hypothesize that this polymorphism influences the adrenergic-mediated thermogenetic and lipolityc activity. Variants of the b3-adrenergic receptor did not contribute to clozapine-induced weight gain. 262 A study of 11 olanzapine-treated Caucasian patients revealed association between CYP2D6 PM alleles (*3 and *4) and increase in body mass index change. 263 The authors argue that CYP2D6 slow metabolism may lead to increased olanzapine concentrations and exposure to weight gain triggers. Polymorphisms in the SNAP-25 gene that codes for a protein involved in synaptic protein have been reported to be marginally associated with weight gain and also to antipsychotic response, 275 although this finding requires confirmation due to the limited size and heterogeneity of the study sample. There is no strong genetic evidence connecting histamine variants with treatment-related weight gain nor with other serotonin (5-HT2A, 5-HT6) or dopamine receptors (D2), G-protein-related proteins (GNB3) and metabolic enzymes (CYP2D6). 262, [264] [265] [266] [267] 276 Variants of the phenylalanine hydroxylase gene (PAH) were investigated for their possible relation with the increased level of phenylalanine observed in TD patients, but no significant associations were observed. 259 However, trends towards association with b 3 -and a 1A -adrenergic receptor variants, and with TNF-a polymorphisms in a study with a limited and heterogeneous sample indicate that further factors may contribute. 276 Additionally, a genomewide linkage study of obesity in patients undergoing treatment with classical antipsychotics identified suggestive linkage (MLS = 2.74) at 12q24. 297 The gene coding for pro-melanin-concentrating hormone, involved in the control of food intake and energy regulation, is located near this region and is a potential candidate gene for drug-induced weight gain. A recent study found differences in genetic patterns associated with weight gain in olanzapine and risperidone treatment. Weight profiles in patients treated with olanzapine were significantly associated with peripheral lipid homeostatic axes SNPs (for apolipoprotien E, apolipprotien A4 and scavenger receptor class B, member 1), whereas weight profiles in patients treated with risperidone were significantly associated with SNPs in the brain appetite peptide regulation (leptin receptor, neuropeptide Y receptor Y5 and paraoxonase 1). 298 This report suggests that there may be common factors shared by all weightinducing drugs, but also drug-specific factors contributing to weight gain.
Neuroleptic malignant syndrome. Severe hypofunction of the dopaminergic system is thought to be the main pathophysiological mechanism of neuroleptic malignant syndrome (NMS). Early manifestations of the NMS are characterized by high fever, consciousness disturbance, autonomic dysfunction, marked rigidity and elevation of serum creatine kinase. Two reports by the same group of investigators have suggested association between a D 2 Taq I polymorphism and NMS, 277, 278 although an independent study did not confirm this association. 279 Interestingly, this polymorphism has now been located inside a novel kinase gene, ANKK1, 299 and further research of this finding is warranted. Additional support for the involvement of the D 2 receptor was provided by the finding of association between the functional À141-C Ins/Del with NMS, with patients possessing the Del allele showing higher incidence of NMS. 280 The À141-C Del allele was initially reported to be associated with a lower expression of the D 2 receptor protein in vitro 159 and higher D2 density in the striatum in vivo, 160 whereas the Taq I A1 allele has been related to lower D2 densities. 280 A SPECT study by Jauss et al. 300 had shown that D2 receptors were completely occupied in patients with acute NMS. This observation, in combination with the genetic results, may suggest that patients with genetically determined lower D2 density may be more susceptible to NMS. However, the in vivo observation of higher D2 density in patients with the À141-C Del allele 160 would not support this theory.
Agranulocytosis. Although infrequent (0.7-3% of treated patients), 281, 286, 301 agranulocytosis is a potentially lethal side effect due to its clinical implications. Immune-mediated toxicity is one of the likely causes of neutropenia. Several reports of associations with major histocompatibility complex (HLA) seem to confirm this hypothesis. [283] [284] [285] Alternatively, it has been suggested that defective oxidative mechanisms may be the cause of agranulocytosis, and that oxidative mitochondrial stress in Europhiles of clozapine-treated patients probably contributes to it. 302 Myeloperoxidases (MPOs) and NADPH oxidases participate in the oxidative mechanism of neutrophils, and polymorphisms in the genes coding for MPO and for a subunit of NADPH oxidase (CYPA) were found related to clozapineinduced agranulocytosis, 281 although a preliminary study failed to find association with MPO variants.
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NOQ1 variants, the oxidative gene involved in the detoxification of drugs, were associated with clozapineinduced agranulocytosis. 286 Finally, the cytokine TNF-a, whose release is stimulated by antipsychotic treatment, contains polymorphisms found in higher frequencies in patients presenting agranulocytosis. 287 The relative high ORs of these findings suggest that these polymorphisms may play an important role in drug-induced neutropenia. Gene variants of CYP2D6, an enzyme initially thought to be involved in the metabolism of clozapine, were not found to increase the risk of agranulocytosis during clozapine treatment. 282 It is important to stress that NMS (incidence 0.3-2%) and agranulocytosis (0.7%) are rare events during antipsychotic treatment. 301, 303 Hence the difficulty in gathering large enough samples to detect moderate genetic effects hinders progress in this area.
Other adverse reactions associated with antipsychotic treatment are not so well reported in the literature. Worth mentioning that drug-drug interactions of typical antipsychotics at the CYP2D6 and CYP3A4 metabolic pathways have been reported to contribute to adverse cardiovascular effects, including prolonged QT interval and sudden death. 304 The findings described in this section indicate complex mechanisms with several factors (receptor oversensitivity, oxidation stress, plasma levels, age and environmental factors) exerting an individual and/or additive effect to the susceptibility to adverse reactions. As in the case of clinical outcome, more than one gene, in combination with clinical (for example, drug dosage) and environmental (for example, diet and smoking habits) is expected to play a role in the development of EPS and other adverse reactions. However, patients presenting specific side effects constitute subgroups in which it is likely that a reduced number of genes contribute to their development, in comparison with the complexity of the mechanism determining clinical outcome. This is already reflected in the number of clear associations reported in relation to side effects. The associations of D3 and 5-HT2C variants with drug-induced TD and weight gain, respectively, are important findings that should find their way into clinical practice. If not alone, due to their relatively moderate effect, for example, the D3 Gly9 increased risk of TD has an OR of 1.17 according to a recent meta-analyses, 238 in combination with other contributing genetic, clinical or environmental factors.
Studies combining clinical and genotyping data to predict side effects Initial attempts of combining clinical variables and genes have been developed for risperidone side effects, 63 risperidone weight gain 305 and TD. 221, 306 One can suspect that some gene variations may be behind some of these clinical predictors. However, these initial studies have suggested that the tested genetic variations appeared to be relatively independent of the clinical predictors. Thus, these genetic predictors, if replicated and validated by additional studies, have the potential of providing additional information that clinicians will have no other way to obtain besides genetic testing. The combination of known clinical predictors and genetic predictors has the potential of reconsidering the use of typical antipsychotics. As the typical antipsychotics are quite less expensive, pharmacogenetic for TD may become cost-effective. 307 As the first marketed atypical antipsychotics are becoming off-patent and less expensive generic forms are available, it is also possible that pharmacogenetic testing for weight gain may become cost-effective. 308 In summary, the authors believed that future tests predicting antipsychotic response may need to include clinical and genetic variables to classify patients more accurately.
Future of research
Pharmacogenetic findings constitute a clear advance towards a future tailoring of antipsychotic treatment to the individual's needs. However, further development of the field can be obtained by application of pharmacogenomic strategies to the identification of novel factors influencing response. Rather than confirming hypothesis using candidate gene approaches, the pharmacogenomic approach envisages genome-wide studies to identify novel proteins and pathways that intervene during antipsychotic treatment. Finally, further research in the field will encompass expansion to other areas such as the study of epigenetic events, which may explain the neurodevelopmental changes associated with schizophrenia aetiology.
The genomic revolution
Although the completion of the human genome project 309 may not have had direct implications for pharmacogenetic research, the subsequent creation of public SNPs and haplotypes databanks [310] [311] [312] has greatly facilitated the search of response-related genes. Tedious and costly searching for natural occurring mutations in treated patients has become nearly obsolete at a time where millions of mutations described in publicly accessible databanks can be used for the purpose of identifying genes involved in response phenotypes. Studies of single mutations putatively associated with a trait are progressively being substituted by association studies in which several polymorphisms in one or several genes are investigated in relation with response phenotypes. Many of these polymorphisms will not have a known functional effect or will not be the direct cause of the investigated traits. However, the genotyping of a high number of polymorphisms increases the chances of using indirect markers that may be in LD with the causal genetic variation. With the rapid increase of information available on human genome variation (more than six million validated SNPs can be found in //ftp.ncbi.nih.gov/snp/), the problem now resides in the SNP selection criteria, particularly when genomewide analyses are attempted. Genotyping of unselected SNPs situated in the same gene or chromosome and likely to be in strong LD may provide similar information. 313 The HapMap project (www.hapmap. org) was created to investigate LD patterns in different populations and to identify informative haplotypes to reduce the number of SNPs required in medium or large-scale investigations. 314 Additionally, the HapMap project has validated and provided information on population frequencies of public databank SNPs thus reducing the chances of investigating nonexistent polymorphisms. This approach has already been successfully used for the identification of genes related to warfarin dose-response levels 315 and to drug-induced weight gain. 297 Nevertheless, this strategy still requires genotyping of large number of variants in clinical samples of moderate-large size. Genotyping techniques have been adapted to these new necessities and a wide range of high-throughput methodologies are available. [316] [317] [318] This is not to say that modest research of a limited number of genes in a moderate sample size is not valuable. Clinical samples showing specific response traits (for example, agranulocytosis, weight gain and improvement of specific symptoms) are highly valuable and difficult to obtain. A limited number of genes may be involved in such traits, thus modest genetic association studies using candidate gene strategies are still of scientific interest.
A range of new high-throughput technologies, ranging from mass spectrophotometry methods (for example, matrix-assisted laser desorption/ionizationtime of flight) to high-resolution hybridization techniques (for example, DNA or RNA arrays) have been developed and are continuously improved to meet the demands of current research needs. 316, 319 Highthroughput techniques are already in use to select representative populations and for the selection of subpopulations likely to respond during phase I and phase II of clinical trials, respectively. 10, 196 Parallel to the development of high-throughput genotyping techniques, an increased need for more advanced and depurated statistical analyses has surged. Several strategies can be used to discriminate between false positives and true findings (for example, more conservative P-levels for significance and corrections for multiple analyses) 320 and specific programmes have been developed for the analyses of array data. 321, 322 Several data mining programmes that facilitate the grouping of genes by function or other criteria have been specifically developed for the analyses of large-scale SNP genotyping and are publicly available (http://www.ncbi.nlm.nih.gov/ Tools/#expression). Although these analyses may restrict findings, genome scans have the potential to identify novel genes related to response phenotypes without the need of previous hypothesis, a clear improvement over candidate gene approaches.
Discerning the mechanism of action of antipsychotics
The advances facilitated by the genomic revolution have contributed to an expansion of the aims of research. The adaptation of new technologies to investigate regulation of gene expression can provide a new insight into the mechanism of action of antipsychotics. High-density microarrays 317 are the preferred method to monitor mRNA levels and determine genome-wide expression alterations and have been the method of choice in most pharmacogenomic investigations. Expression investigations on human brain are hindered by the difficulty of controlling experimental background. For this reason, most pharmacogenomic expression studies have been performed on animal, rat or mice, models. Table 5 summarizes published studies investigating alterations of gene expression caused by antipsychotic treatment using arrays or high-throughput technologies. Investigations in mouse striatum and frontal cortex revealed alterations in the expression of genes involved in neurotransmission and signal transduction after clozapine and haloperidol treatment, and significantly of genes involved in lipid metabolism such as apolipoprotein D (ApoD). 323 Studies using microarrays and rat models have shown that chronic treatment with haloperidol and clozapine modulate the expression of genes involved in synaptic function and regulation of intracellular Ca 2 þ levels in the cortex. 324 Takahashi et al. 325 investigated gene expression in mice injected with clozapine for 20 days and observed alterations in K þ channels, dopamine and serotonin receptor gene expression. Investigations of the expression of 8000 genes in the cortex of haloperidol-and risperidone-treated rats revealed alterations in genes controlling for calcium homeostasis, dopamine system, signal transduction, cell survival, neuronal plasticity and metabolism. 326 Microarray studies in rats treated with clozapine or haloperidol found an increase in the transcription of genes coding for proteins involved in synaptic plasticity and activity in the frontal cortex. 327 Different gene upregulation profiles were observed after clozapine and haloperidol treatment in two separate studies by the same team of investigators. 328, 329 Interestingly, these studies found that Synapsin II, a gene implicated in schizophrenia, was upregulated by haloperidol, and the glucose-dependent insulinotropic polypeptide (GIP), a gene that may have a role in glucose intolerance and weight gain, was upregulated by clozapine. Investigations in the frontal cortex of rats treated with risperidone with 4 weeks revealed differential expression of genes related to neurotransmission, synaptic plasticity and proteosis. 330 Neurotransmission and communication genes were also differential in rats treated with olanzapine, as were genes involved in metabolism, transport, immune response and growth factors. 331 Interestingly, several studies have identified upregulation of protein kinase genes (LR, C and Z) in response to treatment (Table 6 ). In addition, ApoD, MAOB and NMDA3B genes, not directly targeted by antipsychotics but theoretically related to disease aetiology, may be of particular interest. These promising candidate genes are worth investigating via genetic association studies to determine their value as response predictors.
Epigenetic factors
Most research has focused on DNA sequence variation as the cause for disease and treatment alterations. Rat cortex 1200 Clozapine decreased the expression of K þ channel and of prostaglandin D2 synthase, and increased expression of 5-HT2 305 Rat cortex 8000 Haloperidol and risperidone altered expression of genes controlling calcium homeostasis, dopamine system, signal transduction and transcriptional regulation 306 Rat cortex and striatum 8800 Antipsychotic treatment increase expression of genes controlling synaptic activity and plasticity in the frontal cortex. A less specific expression profile is observed in the striatum 307 Rat cortex 1536 Risperidone treatment causes differential expression of genes controlling neurotransmission, synaptic plasticity and proteolysis 310 Rat striatum 1200 Different profile of upregulated genes after haloperidol and clozapine treatment 308, 309 Rat cortex 28 000
Olanzapine treatment causes upregulation of 38 genes and downregulation of 31 genes involved in signal transduction and communication, metabolism, transport and neuronal growth factors 311 The completion of the human genome mapping project revealed a surprisingly low number of genes. 309 Thus genome size and sequence alone could barely explain the evolutionary differences with other species, 332 nor could it explain nonMendelian differences in theoretically genetic traits. The traditional 'genes and environment' combination for complex diseases including schizophrenia has been challenged. 333 Other events, including gene expression modulation processes, have been suggested as motors of adaptation and evolution. This group includes epigenetic events defined as heritable genomic functions that are not contained in the DNA sequence code. Epigenetic events include DNA methylation and histone modifications (for example, acetylation, methylation and phosporylation) and may be inherited during meiotic division. It has been suggested that these epigenetic factors may explain discordances between otherwise genetically similar individuals, for example discordances in monozygotic twins. 334, 335 The dynamic changes of epigenetic events, in contrast to the rigidity of DNA sequence codes, may explain the clinical variations observed during a patient's lifetime (for example, periods of normality combined with critical episodes). 333 Epigenetic signals can be inherited during cell division, although sometimes these changes are reverted during meiosis via a still unknown mechanism. 333 Epigenetic events are responsive to environmental factors although the mechanisms that trigger them are not well understood. A likely hypothesis suggests that environmental insults may influence gene methylation and result in altered expression patterns in brain areas associated with disease aetiology, although epigenetic events may also occur without environmental stimuli. Recent studies have indicated that epigenetic modifications of expression of reelin, BDNF and D 2 genes may confer susceptibility to schizophrenia. 336 Probably one of the more important and consistent findings in this new area is that valproic acid is a potent inhibitor of histone deactylating enzymes. 337 Similar epigenetic findings are expected in relation to antipsychotic response variability. Epigenetic alterations of response-related genes such as dopamine and serotonin have been suggested 336, 338 and differences in DNA methylation in the regulatory regions of D2 and COMT genes have been identified. 335 Already, studies have shown that clozapine and haloperidol induce distinct patterns of phosphorylation of gene expression controlling kinases in the dorsal striatum, indicating a possible explanation for their difference in antipsychotic activity. 339, 340 This is an exciting area which will undoubtedly improve our knowledge on determinants of response variability.
Conclusions
Pharmacogenetic research into genetically determined drug metabolic polymorphisms has already produced valuable findings for psychiatric treatment. Genetic characterization of functional alterations in metabolic enzymes can inform of patients' metabolic status, and therapeutic doses can be adjusted accordingly. Clinical implementation of this practice can have a clear impact in reducing side effects and improving treatment adherence and efficacy. Studies of genetic factors conferring susceptibility to side effects have improved our knowledge on the mechanisms underlying TD, weight gain and other adverse reactions associated to antipsychotic treatment, although no reliable method for their prediction is still available. Initial attempts of combining clinical variables and genes have been developed and the authors believe that future tests predicting antipsychotic response may need to include both clinical and genetic variables to classify patients more accurately. Although still at early stages, preliminary studies have proved that the prediction of general response using genetic information may be feasible and prototype tests are being tried. Expansion of the field to investigate epigenetic factors and the genomic revolution will bring further progress by revealing novel pathways and proteins involved and will improve our understanding of the mechanism of action of antipsychotics. The complexity of the genetic variations and of the statistical analyses of thousands of genetic variants and the difficulty to generalize to the clinical environment in different countries are important challenges for the advancement of pharmacogenetics of antipsychotic response.
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